Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

Clinicians should maintain a high index of suspicion for Cyclospora in patients presenting with prolonged or relapsing watery diarrhea this summer.

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Prefontal transcranial pulse stimulation is associated with antidepressant effects, according to a study published online July 6 in JAMA Network Open. Penny Ping Qin, PhD, from The Hong Kong ...

The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.

Credit: Merck. Supported by the phase 3 CORALreef program, Merck’s once-daily oral macrocyclic peptide offers a non-injectable PCSK9-targeting pathway to significantly clear LDL-C in adults. Lipfendra ...

Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.